Antitrust developments in the health care and pharmaceutical industries were exceptionally active in 2023. From the Federal Trade Commission’s (FTC) challenge of a merger between Amgen Inc. (Amgen) and Horizon Therapeutics plc (Horizon), to joint agency withdrawal of well-established health care merger policy statements, to agency interest in pharmacy benefit managers (PBMs), we review some of the most notable antitrust activity in the health care and pharmaceutical industries over the past year.

Amgen/Horizon

Back in December 2022, Amgen, a California-based biotechnology company, announced its plans to acquire Horizon, an Irish biopharmaceutical company focused on medicines for rare and rheumatic diseases, for around $28 billion. In the announcement for the deal, Amgen noted that Horizon would add a complementary pipeline of medicines to the company’s R&D portfolio, as in fact, none of Amgen’s drugs compete with those of Horizon.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]